US 12,295,943 B2
Apixaban dosing
Paul Goldsmith, London (GB); Bruce Campbell, Cambridge (GB); and Michael Catt, Wellingborough (GB)
Assigned to Closed Loop Medicine Ltd, Cambridge (GB)
Filed by Closed Loop Medicine Ltd., Cambridge (GB)
Filed on Sep. 22, 2023, as Appl. No. 18/472,660.
Prior Publication US 2025/0099441 A1, Mar. 27, 2025
Int. Cl. A61K 31/437 (2006.01); A61P 7/02 (2006.01)
CPC A61K 31/437 (2013.01) [A61P 7/02 (2018.01)] 15 Claims
OG exemplary drawing
 
1. A method for determining and administering a procedure wait time for a patient following withdrawal of a direct oral anti-coagulant, DOAC, in advance of an invasive procedure, the method comprising:
receiving patient data relating to a patient, wherein the patient data includes a kidney function metric of the patient and a DOAC dosage for the patient;
processing, using one or more processors, the patient data with a dosage calculator to determine the procedure wait time for a drug plasma level to fall below an invasive procedure plasma level threshold, wherein the dosage calculator is derived from a plasma level prediction model that predicts DOAC drug plasma levels, and the dosage calculator determines the procedure wait time for the patient based in part on the kidney function metric of the patient; and
administering the procedure wait time in advance of the invasive procedure to reduce a risk of haemorrhage during the invasive procedure.